Introduction
Alzheimer’s disease has long been treated with medications that only manage symptoms. Today, that is changing. The FDA has approved two new disease-modifying therapies that target the underlying biology of early Alzheimer’s. These drugs, Leqembi and Kisunla, are designed to slow cognitive decline by clearing amyloid-beta plaques from the brain. While they offer hope, they also require careful planning, regular medical visits, and a clear understanding of costs and coverage. This guide explains how these treatments work, who qualifies, what insurance covers, and what patients should expect during the entire process.
Understanding the New FDA-Approved Alzheimer’s Drugs
The FDA has granted full approval to lecanemab (brand name Leqembi) and donanemab (brand name Kisunla). Both belong to a class of medications called monoclonal antibodies. These drugs are given through an intravenous (IV) infusion at a clinic or hospital. They are not cures, but clinical trials show they can slow disease progression by roughly 27 to 35 percent over 18 months. This means patients may experience a slower decline in memory, thinking, and daily function compared to those who do not receive treatment.
How These Medications Work
Alzheimer’s disease is linked to the buildup of sticky protein clumps called amyloid-beta plaques in the brain. These plaques interfere with cell communication and trigger inflammation. Leqembi and Kisunla are engineered to bind to these plaques and help the immune system clear them. Brain scans in clinical trials showed reduced amyloid levels after treatment. The slowing of symptoms is modest but meaningful for patients who want to maintain independence longer.
Leqembi and Kisunla: Key Differences
While both drugs target the same protein, they differ in dosing schedules and trial results. Leqembi is given every two weeks through a 60-minute IV infusion. Kisunla is given every four weeks through a 30-minute IV infusion. Kisunla also allows treatment to stop once brain scans show the plaques have been cleared. Leqembi requires ongoing treatment as long as the patient tolerates it. Both medications carry the same primary safety concern: amyloid-related imaging abnormalities, or ARIA.
Who Qualifies for Treatment?
These drugs are not for everyone. They are only approved for early-stage Alzheimer’s disease. This includes mild cognitive impairment (MCI) due to Alzheimer’s or mild dementia. Patients must have confirmed amyloid buildup in the brain. Confirmation requires either a PET brain scan or a cerebrospinal fluid test from a spinal tap. Doctors also check that the patient does not have other types of dementia, such as vascular dementia or Lewy body dementia, since these drugs will not help those conditions.
Age and overall health matter too. Most patients are between 50 and 85 years old. People with bleeding disorders, those taking blood thinners, or those with untreated brain aneurysms may not be safe candidates. A neurologist or memory clinic specialist will review medical history, run imaging tests, and discuss whether the benefits outweigh the risks before starting therapy.
Real Costs and Insurance Coverage
The list price for these medications is high, but actual out-of-pocket costs depend heavily on insurance type and coverage policies. Knowing the numbers upfront helps families avoid surprise bills and plan accordingly.
Medicare and Private Insurance
Medicare covers both drugs under specific conditions. The Centers for Medicare & Medicaid Services (CMS) created a Coverage with Evidence Development (CED) program. This means Medicare will pay for Leqembi and Kisunla only when patients enroll in approved clinical research networks or designated treatment programs. Under Medicare Part B, patients typically pay 20 percent of the approved amount after meeting the annual deductible. For Leqembi, the annual list price is about $26,500. For Kisunla, it is roughly $32,000. With Medicare Part B, the patient share usually falls between $5,000 and $7,000 per year, depending on the deductible and supplemental coverage.
Private insurance plans vary widely. Some insurers cover these drugs after prior authorization, while others require step therapy or deny coverage entirely. Families should call their insurance provider and ask three specific questions: Does the plan cover monoclonal antibodies for Alzheimer’s? What is the prior authorization process? Are infusion centers in-network? Many manufacturers offer patient assistance programs that reduce copays to zero for eligible individuals. These programs often require income verification and proof of residency.
What to Expect During Treatment
Starting a new Alzheimer’s treatment involves a structured medical routine. The first step is a baseline MRI to check for brain bleeds or swelling. If the scan is clear, the infusion begins. Patients visit an infusion center or hospital clinic on a set schedule. The first dose is given slowly to watch for allergic reactions. Subsequent doses follow the approved timeline. Each visit includes a short check-in, the infusion itself, and a brief recovery period.
Patients should plan for transportation, since they cannot drive themselves home after the first few doses. They should also schedule time off work or arrange family support during the first month. The treatment lasts 18 months for Leqembi. Kisunla may end earlier if scans show plaque clearance. Throughout treatment, patients will have regular follow-up visits to track memory, mood, and daily function.
Monitoring and Side Effects
ARIA is the main safety concern. It causes temporary brain swelling or tiny microbleeds. Most cases show no symptoms, but some patients experience headaches, confusion, dizziness, or vision changes. Doctors monitor for ARIA with MRI scans every 3 to 6 months. If ARIA appears, treatment may pause until the brain heals. Patients should report any new headaches, balance issues, or sudden memory drops immediately. Other common side effects include joint pain, fatigue, and mild nausea. These usually improve after the first few weeks.
Next Steps for Patients and Families
Getting started requires a clear action plan. First, schedule an appointment with a neurologist or a certified memory clinic. Bring a list of current medications, past brain scans, and insurance details. Ask for a referral for amyloid testing if it has not been done. Once confirmed, the care team will submit prior authorization forms to insurance. Simultaneously, contact the drug manufacturer’s patient support line to explore copay assistance. Choose an in-network infusion center close to home to reduce travel stress. Keep a treatment log that records infusion dates, MRI results, and symptom changes. Share this log with the care team at every visit.
Conclusion
New FDA-approved Alzheimer’s drugs represent a major shift in how we approach early disease. They do not reverse damage, but they can slow decline and buy valuable time. Success depends on strict eligibility, regular monitoring, and clear insurance planning. Families who understand the costs, follow the medical schedule, and stay in close contact with their care team are best positioned to benefit from these treatments. Early diagnosis, proactive coverage navigation, and consistent follow-up turn a complex process into a manageable path forward.